Netrin-1 and Placenta Accreta

Not Applicable

Completed

• Conditions: Placenta Accreta
• Interventions: Other: Pregnant women at 28-32 weeks; Other: at delivery

• Registration Number: NCT04683562
• Lead Sponsor: Assiut University

Brief Summary

Netrin-1 is a secreted protein, which was first identified as a neuronal guidance factor. It is expressed in a multitude of tissues as pancreas, lung, breast, and placenta. Netrin-1 is a multifunctional protein, involved in cell polarity, adhesion, angiogenesis, apoptosis, migration, morphogenesis, and differentiation of various cell types. Most of netrin-1 activity occur through signaling pathways induced by its two main receptors, DCC (deleted in colorectal cancer) and UNC5H (uncoordinated-5 homolog). Its receptors have been linked to the processes of apoptosis and angiogenesis. In absence of netrin-1, DCC and UNC5H receptors lead to apoptosis. In contrary, in presence of netrin-1, receptors transduce molecular cascades leading to proliferation, differentiation and migration of the cells. Netrin-1 has been involved in the pathogenesis of multiple diseases, as diabetes, cardiovascular diseases, and cancer. Serum Netrin-1 levels were high in preeclamptic patients.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2020-12-21
• Study First Submitted QC: 2020-12-21
• Study First Posted: 2020-12-24
• Study Start: 2021-12-01
• Primary Completion: 2022-06-01
• Study Completion: 2022-06-01
• Status Verified: 2022-08
• Last Update Submitted: 2022-08-19
• Last Update Posted: 2022-08-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 34

Inclusion Criteria

• Age between 20-40 years.
• Singleton pregnancy.
• Women with suspicion of PA by two-dimensional (2D) gray scale imaging and color Doppler flow mapping

Exclusion Criteria

• Multiple pregnancy,
• Fetal anomalies,
• Preterm premature rupture of membranes, or infection
• Any medical disorders, such as thyroid dysfunction, hypertension, and gestational diabetes
• Patients with known bleeding disorders or on anticoagulant therapy.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Normal pregnancy group	Pregnant women at 28-32 weeks	-
Placenta accreta group	at delivery	-
Normal pregnancy group	at delivery	-
Placenta accreta group	Pregnant women at 28-32 weeks	-

Primary Outcome Measures

Name	Time	Method
Placental Netrin-1 level	4 weeks	will be measured by using enzyme-linked immunosorbent assay (ELİSA) in placental homogenate

Trial Locations

Locations (1)

Woman's Health Hospital; 🇪🇬 Assiut, Egypt